EORTC abstracts selected at ESMO 2020 Virtual Congress
17 Sep 2020
5 EORTC abstracts were selected for ESMO 2020 that will take place virtually from 19 until 21 September 2020.
On-Demand Mini Oral Sessions
Mini Oral Session-Sarcoma
A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
- Presentation Number:1628MO
- Date: 18 September 2020
- Speaker: Georgios Kantidakis (Brussels, Belgium)
First-line chemotherapy (CT) in advanced well-differentiated/ dedifferentiated liposarcoma (WD/DD LPS): an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
- Presentation Number: 1629MO
- Date: 18 September 2020
- Speaker: Silvia Stacchiotti
Mini Oral Session – Non-metastatic NSCLC and other thoracic malignancies
LATE BREAKING ABSTRACT: REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- Presentation Number: LBA85
- Date: 18 September 2020
- Speaker: Benjamin Besse (Villejuif, CEDEX, France)
Proffered Paper Session
Proffered Paper Session: Melanoma and Other Skin Cancers
LATE BREAKING ABSTRACT: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial
- Presentation Number: LBA46
- Date: 19 September 2020
- Lecture Time: 17:16 – 17:28
- Speaker: Alexander M. Eggermont (Utrecht, Netherlands)
Poster display session
Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: a multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
- Presentation Number: 1919P
- Date: 17 September 2020
- Speaker: Kate Newbold (Sutton, United Kingdom)
For more information, visit ESMO 2020 online programme.
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024